Idarubicin and ascites Patient Reports February 12, 2012

Idarubicin Side Effects Report #5056337-9
Idarubicin side effect was reported by a Physician from JAPAN on July 03, 2006. Female patient, 57 years of age, weighting 108.0 lb, was diagnosed with acute myeloid leukaemia and was treated with Idarubicin. After drug was administered, patient experienced the following side effects: ascites, asterixis, blood albumin decreased, blood fibrinogen decreased, coma hepatic, condition aggravated, encephalopathy, hepatic failure, hepatitis b . Idarubicin dosage: 18 MG (18 MG, QD), INTRAVENOUS. During the same period patient was treated with CYTARABINE, MITOXANTRONE, VANCOMYCIN HYDROCHLORIDE, ITRACONAZOLE, SULFAMETHOXAZOLE, MEROPEN, AMIKACIN SULPHATE. Patient was hospitalized and became disabled. Patient died on 12/13/2005.

Idarubicin Side Effects Report #4998370-9
Idarubicin side effect was reported by a Physician from JAPAN on Apr 25, 2006. Female patient, 57 years of age, weighting 108.0 lb, was diagnosed with acute myeloid leukaemia and was treated with Idarubicin. After drug was administered, patient experienced the following side effects: ascites, asterixis, hepatitis b , hepatitis b dna assay positive, hepatitis fulminant, oedema peripheral, white blood cell count decreased. Idarubicin dosage: 18 MG (18 MG, QD), INTRAVENOUS. During the same period patient was treated with CYTARABINE, MITOXANTRONE, VANCOMYCIN HYDROCHLORIDE, ITRACONAZOLE, SULFAMETHOXAZOLE, MEROPEN, AMIKACIN SULPHATE. Patient was hospitalized. Patient died on 12/13/2005.

Idarubicin Side Effects Report #5022617-6
Idarubicin side effect was reported by a Physician from JAPAN on May 23, 2006. Female patient, 57 years of age, weighting 108.0 lb, was diagnosed with acute myeloid leukaemia and was treated with Idarubicin. After drug was administered, patient experienced the following side effects: ascites, asterixis, coma hepatic, condition aggravated, decreased immune responsiveness, encephalopathy, hepatic failure, hepatic function abnormal, hepatitis fulminant. Idarubicin dosage: 18 MG (18 MG, QD), INTRAVENOUS. During the same period patient was treated with CYTARABINE, MITOXANTRONE, VANCOMYCIN HYDROCHLORIDE, ITRACONAZOLE, SULFAMETHOXAZOLE, MEROPEN, AMIKACIN SULPHATE. Patient was hospitalized. Patient died on 12/13/2005.